NewAmsterdam Pharma Company N.V. / "Long-term" | Tables in SEC filings

NAMS NewAmsterdam Pharma Company N.V.

Annual report

	As at December 31,
	2024		2023
(In thousands of USD)
Assets
Current assets:
Cash and cash equivalents		771,743		340,450
Prepayments and other receivables		24,272		6,341
Employee receivables		4,951		—
Marketable securities		62,447		—
Total current assets		863,413		346,791
Property, plant and equipment, net		242		46
Operating right of use asset		431		55
Intangible assets		534		170
Long term prepaid expenses		—		35
Total assets		864,620		347,097
Liabilities and Shareholders' Equity
Current liabilities:
Accounts payable		4,744		16,923
Accrued expenses and other current liabilities		13,608		11,398
Deferred revenue, current		6,008		8,942
Lease liability, current		246		60
Derivative earnout liability, current		44,798		—
Derivative warrant liabilities		37,514		12,574
Total current liabilities		106,918		49,897
Deferred revenue, net of current portion		—		1,019
Lease liability, net of current portion		202		—
Derivative earnout liability, net of current portion		—		7,788
Total liabilities		107,120		58,704
Commitments and contingencies (Note 13)
Shareholders' Equity:
Ordinary shares, €0.12 par value; 400,000,000 shares authorized; 108,064,340 and 82,469,768 shares issued and outstanding at December 31, 2024 and 2023, respectively		13,444		10,173
Additional paid-in capital		1,298,160		590,771
Accumulated loss		(558,571)		(316,973)
Accumulated other comprehensive income		4,467		4,422
Total shareholders' equity		757,500		288,393
Total liabilities and shareholders' equity		864,620		347,097

Name and Principal Position		Compensation Component	Involuntary or Good Reason Termination without a Change-in-Control ($)		Involuntary or Good Reason Termination in Connection with a Change-in-Control ($)
Michael Davidson, M.D.	(1)	Cash Severance		931,950		931,950
		Long-term Incentives		—		41,344,023
		Benefits and Perquisites		23,871		23,871
		Total:		955,821		42,299,844
Ian Somaiya	(1)	Cash Severance		678,600		678,600
		Long-term Incentives		—		10,766,007
		Benefits and Perquisites		35,711		35,711
		Total:		714,311		11,480,318
John Kastelein, M.D., Ph.D. FESC	(2)	Cash Severance		486,046		486,046
		Long-term Incentives		—		—
		Benefits and Perquisites		—		—
		Total:		486,046		486,046
Juliette Audet	(3)	Cash Severance		601,541		601,541
		Long-term Incentives		—		1,082,500
		Benefits and Perquisites		—		—
		Total:		601,541		1,684,041
Douglas Kling	(1)	Cash Severance		700,000		700,000
		Long-term Incentives		—		12,385,275
		Benefits and Perquisites		35,711		35,711
		Total:		735,711		13,120,986

Table search / NewAmsterdam Pharma Company N.V. / "Long-term"